What Now for Remdesivir?
The World Health Organization advised against using remdesivir to treat patients hospitalized with COVID-19, citing a recent WHO-sponsored study that [...]
COVID-19: Second Assessment Update
According to ICER, the totality of evidence no longer supports an assumption of survival benefit from remdesivir. ICER based its [...]
ICER Provides Second Update to Pricing Models for Remdesivir
According to ICER, the totality of evidence no longer supports an assumption of survival benefit from remdesivir. ICER based its [...]
ICER Launches Customizable COVID-19 Cost-Effectiveness Model
The Institute for Clinical and Economic Review (ICER) announced the launch of a cloud-based platform that allows customization of model [...]
What is the Most Effective Way to Navigate Pricing Models for COVID-19 Innovations?
Preliminary clinical benefit information is translated into longer-term health benefit and economic value through pricing models, making them invaluable for [...]
Advertisement
